Literature DB >> 33223091

Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders.

Bhaskar Roy1, Robert Griggs2.   

Abstract

Increased understanding of disease pathophysiology and advances in gene therapies and drug technologies are revolutionizing treatment of muscular dystrophies and motor neuron disorders (MNDs). New drugs have been approved for Duchenne muscular dystrophy, spinal muscular atrophy, and amyotrophic lateral sclerosis. For other diseases, new targets have been identified, and new therapies are in clinical trials. The impact of such therapies will be fully understood only in the next decades. Cost burden and accessibility are major challenges in the wide application of new drugs. This article reviews advances in gene therapies, newly approved drugs, and therapeutic promises in muscular dystrophies and MNDs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene therapy; Motor neuron disorders; Muscular dystrophies; Neuromuscular diseases; Neurotherapeutics

Year:  2021        PMID: 33223091     DOI: 10.1016/j.ncl.2020.09.005

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  3 in total

Review 1.  Congenital or Early Developing Neuromuscular Diseases Affecting Feeding, Swallowing and Speech - A Review of the Literature from January 1998 to August 2021.

Authors:  Lotta Sjögreen; Lisa Bengtsson
Journal:  J Neuromuscul Dis       Date:  2022

Review 2.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

3.  Selective ablation of Nfix in macrophages attenuates muscular dystrophy by inhibiting fibro-adipogenic progenitor-dependent fibrosis.

Authors:  Marielle Saclier; Giuseppe Angelini; Chiara Bonfanti; Giada Mura; Giulia Temponi; Graziella Messina
Journal:  J Pathol       Date:  2022-04-13       Impact factor: 9.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.